🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Cutting-edge heart failure research, digital health hurdles & Norway's trial approach - explored in this 3-part podcast with Prof. Peder Myhre Peder L. Myhre MD, PhD & Jonathan Sackier. Tune in: hubs.la/Q03lbr_K0

🎧 What an inspiring listen by Peder L. Myhre MD, PhD on tackling heart failure—from cutting-edge HF research to biomarker-driven care, global challenges of implementing digital health, and how Norway is reshaping participation in cardiology clinical trials. emjreviews.com/cardiology/pod…

Inflammation is central to development/progression HF. This review unpacks the role of immune pathways, biomarkers like CRP/IL-6, and comorbidities like diabetes and obesity—while exploring the promise (and limits) of anti-inflammatory therapies in HF (link.springer.com/article/10.100…).

Very important topic. Many cases of HFpEF are simply a deficiency disorder. A deficiency of exercise!! 🏃‍♂️

Straight from a beautiful Norwegian national day celebration to Belgrade for European Society of Cardiology #HeartFailure2025 ! Can’t wait to see all my HF friends and learn more. 📍Join us Tuesday 8.30 for a Late Braker registry presentation from 🇳🇴 Kristian Berge & 🇮🇹Riccardo M. Inciardi, MD, PhD

Selfie after birthday party ⁦Alexandre Mebazaa⁩ ⁦Carolyn Lam⁩ ⁦Karen Sliwa⁩ ⁦Peder L. Myhre MD, PhD⁩

Data from #FINEARTS-HF supporting the efficacy of EARLY initiation of GDMT following hospitalization for HF. Ankeet S. Bhatt, MD, MBA 💫 To be confirmed REDEFINE-HF: clinicaltrials.gov/study/NCT06008…

Super interesting data from Safia Chatur, MD scottdavidsolomon and #FINEARTS-HF: Consistent safety and efficacy of finerenone across the eGFR spectrum in HF, and seems more favorable with respect to safety in lower eGFR compared to spironolactone (TOPCAT)

New data from EMPEROR-Preserved: patients with more severe diastolic dysfunction seems to experience greater benefit from empagliflozin! Highly significant interactions

Fantastic late breaker session at #HeartFailure2025 ‼️ 🇳🇴🇸🇪🇮🇹 doing really well on #GDMT uptake - especially after the 2021 European Society of Cardiology guidelines, including improvements in outcomes 👏🏻 ⭐️⭐️⭐️ Kristian Berge Riccardo M. Inciardi, MD, PhD #FelixLindberg

2024 European blood pressure guidelines have sparked controversy, with their implications still unclear. We have applied these guidelines to a cohort study. Check it out European Society of Cardiology Journals Stroke AHA/ASA Tidsskriftet European Society of Cardiology @ heart.bmj.com/content/early/…

#CONFIDENCE 1⃣ + 1⃣ = 2⃣ Remarkably, kidney protection with combination therapy mathematically identical to what would be expected based on each monotherapy Finerenone (0.68) * Empagliflozin (0.71) Combination (Expected if Fully Additive): 0.48 Combination (Observed): 0.48

We had the pleasure to host Muthu Vaduganathan for a mini-tour of Oslo with talks for nephrologists (#NSN2025), cardiologists, grand rounds and a research seminar. A true leader in cardio-renal-metabolic disease and such a friendly guy! We are so grateful for your visit!🙏

DOACs may offer a safer, simpler alternative to warfarin for LVAD patients—especially with HM3. This review explores emerging data, device-specific considerations, and the need for prospective trials to guide anticoagulation for LVADs (link.springer.com/article/10.100…). #HREV Ndakotsu A.K

Obesity drives a unique, early-onset form of HFpEF—often underdiagnosed. Yet, no guidelines recommend screening. This review outlines why systematic screening in obesity is overdue and proposes a tailored approach (link.springer.com/article/10.100…). #HREV Josephine Harrington, MD Marat Fudim, MD MHS

#GDMTworks 🇳🇴

This is super interesting. Low ApoM seems to be a key player in HF/CKM. I think we will learn much more about this as a potential therapeutic target the next decade…

Athlete’s heart vs. cardiomyopathy—where’s the line? 🫀 This review breaks down how to distinguish physiologic remodeling from early-stage hypertrophic, dilated, or arrhythmogenic CM using imaging. A practical guide to navigating the “gray zone” (link.springer.com/article/10.100…). #HREV

AF and HFpEF co-exist and drive CV risk. Managing AF in HFpEF requires an integrated approach—HF therapy, rhythm or rate control, and stroke prevention. There is a growing case for early rhythm control via ablation (link.springer.com/article/10.100…). #HREV Paula Rambarat Jonathan Piccini, MD, MHS

Absolutely thrilled about the recent regulatory clearances of our cardiac amyloidosis (CA) detection model. This is a game-changer in early CA diagnosis—bringing speed, accuracy, and scale to a condition that’s too often missed or delayed. Proud of the impact this will have!